NCT05788081 - Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

January 1, 2027

Study Completion Date

June 1, 2027

Conditions

Follicular Lymphoma Stage IIFollicular Lymphoma Stage IIIFollicular Lymphoma Stage IV

Interventions

DRUG

golcadomide

BMS-986369 is an orally administered Cereblon-modulating compound

DRUG

Nivolumab 10 MG/ML

Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.

DRUG

Rituximab

Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions

Trial Locations (5)

Austin Health, Heidelberg

Eastern Health, Box Hill

Grampians Health, Ballarat

University Hospital Geelong, Barwon Health, Geelong

Fiona Stanley Hospital, Perth